Form D · Pharmaceuticals

Lengo Therapeutics, Inc.

Menlo Park, CA · CIK 0001808546

Offering snapshot reported Apr 30, 2021 · SEC filing

Reported sold
$17.7M
Offering amount: $17.7M
Investors reported
4
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 26, 2020
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$8.85M$17.7MApr 9, 2020: $4,400,000.00Apr 9, 2020Apr 30, 2021: $17,700,001.00Apr 30, 2021

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$4,400,000 → $17,700,001
  • Reported investors1 → 4

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 30, 2021Amendment$17,700,001$13,300,001vs Apr 9, 20204SEC filing
Apr 9, 2020Initial$4,400,000No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-364705

Source: Form D, filed Apr 30, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Steve Bailey Executive
Anna Chen Executive
Daniel Estes, Ph.D. Director, Executive
Helen Jenkins Director, Executive
David Johnson Director
Tracy Saxton, Ph.D. Director
Roger Ulrich, Ph.D. Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
70 Willow Road, Suite 200
Menlo Park, CA, 94025